Eisai highlights next-generation Alzheimer's research, Talawar Therapeutics secures $285 million to advance a first-in-class bispecific antibody, and the FDA approves a new biologic for thyroid eye disease.
This episode explores a first-in-class antibody entering the clinic for kidney fibrosis, the world's first approved bispecific ADC, and a major acquisition that strengthens AbbVie's immunology pipeline.
Innovent advances a trispecific antibody into phase 3 multiple myeloma testing, Bionyra enters the crowded TL1A race in inflammatory bowel disease, and Insilico Medicine partners with SK Biopharmaceuticals to apply AI to neuroimmune and CNS drug discovery.
Today's BioPharm Brief covers an FDA filing acceptance for Roche's Lunsumio and Polivy combination in lymphoma, a pediatric expansion for Merck's CAPVAXIVE vaccine, and a key advisory committee meeting for Moderna's mRNA-based flu vaccine.
Early clinical data highlight advances in bispecific antibodies and immune modulation, with new findings in Type 2 inflammatory diseases, alopecia areata, and platinum-resistant ovarian cancer.
New clinical data highlight advances in endocrine, metabolic, and rare disease drug development, with positive updates from MBX Biosciences, Gan & Lee Pharmaceuticals, and Novartis.
New developments in CAR-T cell therapy, antibody-drug conjugates, and biosimilars highlight continued innovation across oncology and immunology.
This week's BioPharm Brief highlights City Therapeutics' efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly's oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial.
In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory and reimbursement pressure, and embed technology into the operational infrastructure of care delivery.
This week's BioPharm Brief highlights City Therapeutics' efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly's oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial.
Sanofi secured European approval for a subcutaneous formulation of Sarclisa in multiple myeloma, Pfizer expanded HYMPAVZI's FDA-approved use in hemophilia, and Johnson & Johnson agreed to acquire Firefly Bio to strengthen its KRAS-focused oncology pipeline.
In this episode of The BioPharm Brief, we cover the FDA approval of Lupin's interchangeable ranibizumab biosimilar Ranluspec, a new iPSC cell therapy manufacturing partnership between Made Scientific and Pluristyx, and emerging research on TIGIT as a potential immunotherapy target in pancreatic cancer.
Today's biopharmaceutical news highlights an FDA breakthrough designation in spinal muscular atrophy, an expanded oncology collaboration focused on tumor activated bispecifics, and a new biosimilar launch for retinal diseases in Europe.
Daily biopharma update covering RNA exon editing licensing, gene therapy clinical data, and preclinical rare disease collaboration advances across the biotech sector.
Today’s BioPharm Brief covers FDA draft guidance aimed at streamlining rare disease gene therapy development, Phase 3 trial updates involving dual survival endpoints in oncology programs, and Eli Lilly’s $1.2 billion licensing deal for a GLP-2 therapy in short bowel syndrome.
New data in lung cancer and solid tumors highlight the growing impact of next-generation immunotherapies, including bispecific antibodies and TCR-based therapies, as developers report encouraging efficacy across difficult-to-treat patient populations.
Pfizer’s $10.5 billion oncology collaboration with Innovent, early clinical progress for a novel PD-1/IL-2 fusion protein, and promising Phase III hepatitis B cure data highlight today’s key developments in biopharmaceutical innovation.
Olezarsen’s latest pancreatitis data, Apogee’s advancing atopic dermatitis program, and Jade Biosciences’ first-in-human autoimmune trial highlight continued momentum in RNA therapeutics, immunology, and antibody development across the biopharmaceutical industry.
Today’s BioPharm Brief covers promising Phase 1 data for Eli Lilly’s gene-editing therapy VERVE-102, evolving CAR-T and bispecific competition in multiple myeloma, and new preclinical findings for a Parkinson’s disease regenerative therapy candidate.
Today’s BioPharm Brief covers major developments in oncology, rare disease therapeutics, and ADC manufacturing, including positive Phase 3 data for Kelun-Biotech’s sac-TMT in triple-negative breast cancer, promising hypochondroplasia results for vosoritide, and new perspectives on risk-based cleaning validation for highly potent drug manufacturing.
This edition of The BioPharm Brief highlights major advances in obesity, oncology, and regenerative medicine, including Merck’s Phase 3 ADC study in metastatic colorectal cancer, Eli Lilly’s promising retatrutide obesity trial results, and manufacturing progress supporting Klotho cell therapy development. Together, these updates reflect the biopharma industry’s accelerating focus on targeted therapies, next-generation weight loss drugs, and scalable cell therapy innovation.
New clinical trial updates highlight advances in RNA editing for alpha-1 antitrypsin deficiency, semaglutide data in MASH liver disease, and improved joint outcomes in psoriatic arthritis treatment comparisons.
Today’s BioPharm Brief covers how biopharma companies are leveraging next-generation platform technologies—from CNS-targeted gene therapy and AI-driven R&D to antibody-cleaving biologics partnerships—to improve therapeutic precision, reduce development barriers, and expand access to advanced medicines.
Today’s BioPharm Brief covers major developments in antibody-drug conjugates, early-stage HER2-positive breast cancer treatment, and the expanding biosimilars market.
AstraZeneca reported encouraging bladder cancer data for Imfinzi plus BCG, Imviva shared early remission findings for allogeneic CAR-T therapy in lupus, and Biogen expanded its rare disease pipeline through its acquisition of Apellis Pharmaceuticals.
Today’s BioPharm Brief covers Phase III clinical trial advances in bladder cancer from AstraZeneca , new in vivo CAR-T financing from Create Medicines, and positive Duchenne muscular dystrophy gene therapy results from REGENXBIO.
Today’s BioPharm Brief covers a major gene therapy milestone, an FDA Breakthrough Therapy designation in rare cancer, and a multi-billion-dollar oncology partnership shaping global drug development pipelines.
Today’s podcast recaps news centered on FcRn modulation, biomarker-guided therapies, and accelerated ADC pathways, which all highlight precision-focused strategies for high-unmet-need diseases.
Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson & Johnson’s dual-pathway approach to inflammatory bowel disease treatment.
Today’s BioPharm Brief covers promising AML remission data from Aptevo, encouraging Duchenne muscular dystrophy trial results from Entrada Therapeutics, and a new GSK licensing deal expanding cardiometabolic RNA therapy development.
